Latest Content

This supplement was supported by AstraZeneca.

Cancer survivors face lasting skin, hair, and nail reactions; dermatology follow-up and treatments can restore appearance, improve quality of life, and monitor risks.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.

Mental Health Awareness Month puts a spotlight on the prevalence of mental illness throughout the country, as well as reduces the stigma surrounding it.

Durvalumab plus BCG also marks the first new treatment in over 30 years for high-risk non–muscle-invasive bladder cancer.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

This article provides a commentary on a news feature published on AJMC.com in 2025 titled “AI Seen as Key to Reducing Health Care Claim Denials, Survey Finds.”

Health plan infrastructure and patient reporting are underutilized, powerful tools for identifying food insecurity, Jonathan Wrathall, PhD, argues.